Diabetes drug could help heart failure patients with leaky valve
NCT ID NCT06027307
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether enavogliflozin, a diabetes drug, can improve outcomes in people with heart failure and a leaky tricuspid valve. About 541 participants will receive either the drug or a placebo for 18 months. Researchers will track heart-related events, valve worsening, and kidney function to see if the drug helps.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Enavogliflozin (a diabetes drug that helps the heart and kidneys)
What this could lead to
If it works, this could offer a new treatment option for heart failure patients with a leaky tricuspid valve, potentially reducing hospitalizations and improving survival.
What could go wrong
This is a single phase 3 trial with 541 participants, so results may not apply to all patients. The drug may not show significant benefit over placebo, and side effects like dehydration or kidney issues are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, South Korea
-
Inha University Hospital
Incheon, South Korea
-
Samsung Medical Center
Seoul, South Korea
-
Seoul National University Hospital
Seoul, South Korea
-
Yonsei University Medical Center
Seoul, South Korea